The Macular Minute Episode 3
with Sobha Sivaprasad
Licensed Posology for EYLEA® (aflibercept) 8 mg in the UK
This episode has been removed as of June 2025 due to an update in the EYLEA 8 mg licensed posology. The current EYLEA 8 mg Summary of Product Characteristics (SmPC) can be found here.
This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.
Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.
Prescribing information for EYLEA® (aflibercept) 2 mg can be found here.
Sobha Sivaprasad
Professor Sobha Sivaprasad is a medical retina consultant ophthalmologist at Moorfields eye Hospital with expertise in Diabetic Retinopathy, Retinal Vein Occlusions, Macular Degeneration and other retinal conditions. She is the director of the National Institute for Health and Care Research (NIHR) Moorfields Clinical Research Facility and the chair of the Scientific Committee of the Royal College of Ophthalmologists, and has published over 500 peer-reviewed articles.
Speaker Disclosures
Financial support from AbbVie, Amgen, Apellis Pharmaceuticals, Bayer, Biogen, Boehringer Ingelheim, Eyebiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Kriya Therapeutics, Novartis, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Roche, Sanofi and Stealth BioTherapeutics
References
- EYLEA® 40 mg/mL Summary of Product Characteristics.
- EYLEA® 114.3 mg/mL Summary of Product Characteristics.
PP-EYL-GB-2888 | July 2025